530
Views
9
CrossRef citations to date
0
Altmetric
Review

Immunotherapy for malignant mesothelioma: reality check

, &
Pages 1167-1176 | Received 09 Aug 2016, Accepted 22 Sep 2016, Published online: 06 Oct 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Thivyan Thayaparan, Roseanna M. Petrovic, Daniela Y. Achkova, Tomasz Zabinski, David M. Davies, Astero Klampatsa, Ana C. Parente-Pereira, Lynsey M. Whilding, Sjoukje JC van der Stegen, Natalie Woodman, Michael Sheaff, Jennifer R. Cochran, James F. Spicer & John Maher. (2017) CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. OncoImmunology 6:12.
Read now

Articles from other publishers (8)

Geraldine M. O’Connor & Emyr Y. Bakker. (2022) Patient-Level Omics Data Analysis Identifies Gene-Specific Survival Associations for a PD-1/PD-L1 Network in Pleural Mesothelioma. BioMedInformatics 2:4, pages 580-592.
Crossref
Glen Reid, Sonja Klebe, Nico van Zandwijk & Anthony M. George. (2021) Asbestos and Zeolites: from A to Z via a Common Ion. Chemical Research in Toxicology 34:4, pages 936-951.
Crossref
Xiyong Fan, Chris McLaughlin, Cleo Robinson, Jason Ravasini, Karin Schelch, Thomas Johnson, Nico Zandwijk, Glen Reid & Anthony M. George. (2019) Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. FASEB BioAdvances 1:9, pages 550-560.
Crossref
Harald Oey, Marissa Daniels, Vandana Relan, Tian Mun Chee, Morgan R Davidson, Ian A Yang, Jonathan J Ellis, Kwun M Fong, Lutz Krause & Rayleen V Bowman. (2019) Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis 40:6, pages 724-734.
Crossref
Binghao Li, Yang Zeng, Patrick M. Reeves, Chongzhao Ran, Qiuyan Liu, Xiying Qu, Yingying Liang, Zhao Liu, Jianping Yuan, Pierre R. Leblanc, Zhaoming Ye, Ann E. Sluder, Jeffrey A. Gelfand, Timothy A. Brauns, Huabiao Chen & Mark C. Poznansky. (2018) AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression. Cancer Immunology Research 6:5, pages 539-551.
Crossref
Nico van Zandwijk, Nick Pavlakis, Steven C Kao, Anthony Linton, Michael J Boyer, Stephen Clarke, Yennie Huynh, Agata Chrzanowska, Michael J Fulham, Dale L Bailey, Wendy A Cooper, Leonard Kritharides, Lloyd Ridley, Scott T Pattison, Jennifer MacDiarmid, Himanshu Brahmbhatt & Glen Reid. (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology 18:10, pages 1386-1396.
Crossref
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao, Paul Taylor, Federica Grosso, Scott J Antonia, Anna K Nowak, Maria Taboada, Martina Puglisi, Paul K Stockman & Hedy L Kindler. (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology 18:9, pages 1261-1273.
Crossref
Bibhusal Thapa, Adriana Salcedo, Xihui Lin, Marzena Walkiewicz, Carmel Murone, Malaka Ameratunga, Khashyar Asadi, Siddhartha Deb, Stephen Arthur Barnett, Simon Knight, Paul Mitchell, D. Neil Watkins, Paul C. Boutros & Thomas John. (2017) The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. Journal of Thoracic Oncology 12:5, pages 850-859.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.